Research Article
Long-Term Mortality Outcomes According to the Frequency of Right Ventricular Pacing in Veterans
Table 3
Clinical characteristics in Washington, DC VAMC subgroup.
| | <20% RVP | >80% RVP | |
| | Number of patients | 26 | 148 | | | Age at implant | 73.1 | 74.5 | | | Rate responsiveness | 23 (88%) | 146 (99%) | | | Pacemaker type: | | | | | Single chamber | 10 (38%) | 22 (15%) | | | Dual chamber | 16 (62%) | 126 (85%) | | Coronary artery disease | 9 (34.6%) | 71 (48.0%) | | | Diabetes mellitus | 8 (30.8%) | 48 (32.4%) | | | Dyslipidemia | 15 (57.7%) | 76 (51.4) | | | Heart failure | 4 (15.4%) | 33 (22.3%) | | | Hypertension | 19 (73.1%) | 113 (76.4%) | | | ACE/ARB | 14 (53.8%) | 87 (58.8%) | | | Aspirin | 13 (50%) | 73 (49.3%) | | | 12 (46.2%) | 62 (41.9%) | | | Calcium channel blocker | 4 (15.4%) | 26 (17.6%) | | | Diuretic | 13 (50%) | 72 (48.6%) | | | Statin | 15 (57.7%) | 65 (43.9%) | |
|
|
ACE/ARB Angiotensin-converting enzyme inhibitor and/or Angiotensin receptor blocker.
RVP right ventricular pacing.
|
